Guardant Health Receives FDA Approval for Guardant360 CDx Companion Diagnostic

Guardant Health announced that it has received FDA approval for Guardant360 CDx as a companion diagnostic for Boehringer Ingelheim's HERNEXEOS. This approval represents an important step in the development of precision medicine for HER2-positive lung cancer patients.

The Guardant360 CDx is designed to identify patients who are eligible for the HERNEXEOS treatment, offering personalized healthcare and improving patient outcomes.

This approval demonstrates Guardant Health's expertise in developing innovative solutions for the healthcare industry and reinforces its commitment to advancing cancer diagnostics.